Yahoo Finance Live looks to Amazon shares following the tech giant's latest earnings report.
Amazon shares slide lower in the after-hours trading session despite reporting a Q4 earnings beat.
Shares of apparel company Hanesbrands (NYSE: HBI) dropped like a rock on Thursday after the company provided lackluster financial guidance and announced some substantial pivots to management's priorities. As of 11:40 a.m. ET, Hanesbrands stock was down 23% -- particularly painful, considering the market is soaring today. On one hand, fourth-quarter revenue of $1.47 billion beat guidance from Hanesbrands' management.
Two major automakers want to put more fuel cell vehicles on the road -- and Plug Power investors took note.
Investors got a reminder of the capabilities of Palantir Technologies' (NYSE: PLTR) products, helping to reinforce the bull case for the stock. Palantir came to market in late 2020 to great enthusiasm, based largely on the reputation of its technology. The data-analytics provider is credited with helping the Pentagon find Osama bin Laden and with flagging the Bernie Madoff Ponzi scheme.
Amazon reported its Q4 2022 earnings on Feb. 2.
There's more evidence now favoring medical marijuana legalization. But medical marijuana is already legal in most states.
Open Text Corporation (NASDAQ: OTEX), (TSX: OTEX), today announced its financial results for the second quarter and year ended December 31, 2022.
Yahoo Finance Live’s Julie Hyman breaks down oil earnings.
Higher oil price is likely to have aided BP's Q4 earnings.
In this market, the last thing investors have been rewarding this earnings season is a bottom-line miss vs. expectations of any magnitude. Except if you are Meta.
Shares of connected-TV platform company Roku (NASDAQ: ROKU) jumped 41.3% in January, according to data provided by S&P Global Market Intelligence. Roku's gains seem to be based on some fundamental improvements to the business, which is good. Roku kicked off the new year by launching its own line of smart TVs.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $317.27, marking a -1.8% move from the previous day.
Leading iBuyer Opendoor (NASDAQ: OPEN) was having an excellent day on Thursday. As of 3 p.m. EST, the real estate disruptor's stock had risen by 14% for the day and has now more than tripled from its 52-week low in just over a month. There isn't any company-specific news driving the news higher, but there has been a surge in optimism for the real estate market in general.
For the third day in a row, Tesla (NASDAQ: TSLA) stock is riding higher -- up 4.3% as of 10:10 a.m. ET. The Federal Reserve's decision to raise interest rates only 25 basis points yesterday is probably part of the reason for that -- indeed, growth stocks in general seem happy to run today, with the entire Nasdaq up nearly 2%. Tesla's plan to cut the prices of its electric cars, you see -- not just in the U.S., but in China as well -- is having its intended effect of stoking consumer demand.
Change doesn't have to be bad.
A short squeeze occurs when short-sellers rush to cover their positions on a stock. The sudden rush of buying can quickly push a stock price higher. After a tough market year in 2022, some stocks have built up large short-seller followings, potentially priming the pump for a new wave of short squeezes.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Following the company's previous earnings release, Cramer apologized to his audience, saying that his trust in Meta's management team was "ill-advised" and that his bullish hubris was "extraordinary, and I apologize."
Tenax Therapeutics Inc (NASDAQ: TENX) received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The patent is expected to last until 2040. It will provide the company with substantial added intellectual property (IP) protection for using levosimendan in treating PH-HFpEF patients in th